GEMYSIS
DEAD

Serial Number

88811294

Owner

Gemysis Inc.

Attorney

Thomas Druan

Filing Date

Feb 26, 2020

Add to watchlist:

No watchlists yet
View on USPTO

GEMYSIS Trademark

Serial Number: 88811294

GEMYSIS is a trademark filed by Gemysis Inc. on February 26, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Gemysis Inc.

Silver Lake Executive Campus
Newtown, PA 18940

Entity Type: 03

Trademark Details

Filing Date

February 26, 2020

Registration Date

Not Registered

Published for Opposition

December 22, 2020

Goods & Services

Pharmaceutical preparations for the treatment of cancer and tumors; pharmaceutical preparations for the treatment of immune disorders; pharmaceutical preparations for immunotherapy through genetically engineered cell therapy; kits comprised of cells and pharmaceutical preparations, namely, kits for the treatment of cancer and tumors for medical or clinical purposes; kits comprised of cells and pharmaceutical preparations, namely, kits for the treatment of immune disorders for medical or clinical purposes; cell therapy products, namely, genetically engineered cells and medical preparations for the treatment of cancer and tumors for medical or clinical purposes; cell therapy products, namely, genetically engineered cells and medical preparations for the treatment of immune disorders for medical or clinical purposes; biological and pharmaceutical preparations for the treatment of cancer and immune disorders using genetically engineered cells

Business services, namely, wholesale distributorship services in the field of cellular immunotherapies for the treatment of cancer and tumors; business services, namely, wholesale distributorship services in the field of cellular immunotherapies for the treatment of immune disorders; pharmaceutical sales promotion for others

Pharmaceutical research and development; medical and scientific research and development of cellular immunotherapies for the treatment of cancer and tumors; medical and scientific research and development of cellular immunotherapies for the treatment of immune disorders; conducting clinical trials for others regarding pharmaceutical preparations and drugs in the field of immunotherapy and cell therapy; scientific and technological services, namely, research, analysis, and clinical trials for others in the field of cellular immunotherapy; providing medical and scientific research information in the field of cellular immunotherapies; compiling scientific and or clinical data, in particular patient data and data from clinical studies, for research purposes in the fields of cell therapy, genetics, immunology, rare diseases, and oncology; licensing of technology in the fields of pharmaceuticals and gene therapy

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 18, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 18, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2023 EXRA
SOU EXTENSION 5 GRANTED
Aug 8, 2023 EX5G
SOU EXTENSION 5 FILED
Jul 24, 2023 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 24, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 9, 2023 EXRA
SOU EXTENSION 4 GRANTED
Mar 8, 2023 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 3, 2023 AITU
SOU EXTENSION 4 FILED
Feb 16, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 16, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 2, 2022 EXRA
SOU EXTENSION 3 GRANTED
Jul 31, 2022 EX3G
SOU EXTENSION 3 FILED
Jul 31, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
Jul 31, 2022 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 25, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 25, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 25, 2022 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 17, 2022 EXRA
SOU EXTENSION 2 GRANTED
Feb 15, 2022 EX2G
SOU EXTENSION 2 FILED
Feb 15, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 15, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 13, 2021 EXRA
SOU EXTENSION 1 GRANTED
Aug 11, 2021 EX1G
SOU EXTENSION 1 FILED
Aug 11, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 11, 2021 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 1, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 1, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 1, 2021 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 16, 2021 NOAM
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 10, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 10, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 10, 2021 REAP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 22, 2020 NPUB
PUBLISHED FOR OPPOSITION
Dec 22, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 2, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 13, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 13, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 13, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 13, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 13, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 12, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 11, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 11, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 15, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 15, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 15, 2020 CNRT
ASSIGNED TO EXAMINER
May 15, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 7, 2020 NWOS
NEW APPLICATION ENTERED
Mar 5, 2020 NWAP